

# Effect of Dry Hydrogen Peroxide on *Candida auris* Environmental Contamination

J. Sanguinet<sup>1</sup>, G. Marshall<sup>1</sup>, J. Moody<sup>2</sup>, K. Sands<sup>2</sup>  
Sunrise Hospital & Medical Center, Las Vegas, NV<sup>1</sup>  
HCA Healthcare, Clinical Services Group, Nashville, TN<sup>2</sup>

**Contact Information:**  
Sunrise Hospital & Medical Center  
Infection Prevention  
Gerard.Marshall@hcahealthcare.com  
Jennifer.Sanguinet@hcahealthcare.com



## BACKGROUND

- Candida auris*, (*C. auris*), is an emerging pathogen which exhibits broad antimicrobial resistance
- C. auris* causes highly morbid infections
- Reported cases increased 318% in 2018 when compared to the average number of cases reported in 2015 to 2017.
- Local increases of *C. auris* showed prolonged survival on surfaces where standard disinfectants may not achieve adequate disinfection.
- Persistent patient colonization and constant environmental recontamination posed an infection risk that may be mitigated by no touch disinfection systems.
- Dry Hydrogen Peroxide (DHP) technology is designed to provide continuous and automated delivery of DHP to reduce the microbial contamination in the hospital setting.
- Previous studies have demonstrated significant reductions in microbial bioburden within hospital environments.

## OBJECTIVES

- Assess the presence of *C. auris* environmental contamination in multiple clinical areas (both patient and healthcare worker).
- Evaluate the efficacy of continuous dry hydrogen peroxide (DHP™) exposure on *C. auris* environmental contamination.
- Identify if a statistically significant association is identified between the absence of *C. auris* and the presence of the Synexis® DHP, and trend to the reduction of *C. auris* cases.

## METHODS



- Conducted in a large tertiary care center where multiple patients were identified as either infected or colonized with *C. auris*.
- DHP-emitting systems were installed in the ventilation systems dedicated to the Adult Burn Intensive Care and Children's Cardiac Intensive Care units.
- Composite surface samples were collected in a sample of patient rooms, shared clinical workspaces, and staff personally used devices among units with current *C. auris* patients.
- The samples included:
  - "high touch" surfaces near the patient
  - the general area of the patient room
  - shared medical equipment for the unit
  - shared staff work areas
  - equipment dedicated to individual staff members.
- Presence of *C. auris* was determined by polymerase chain reaction (PCR).
- Association between DHP exposure and *C. auris* contamination was determined by Fisher's exact test.

## RESULTS

In the presence of patients previously identified with *C. auris*:

- No DHP System Present:
  - Baseline samples were collected from units without DHP on days 1, 7, 14, and 28.
  - At baseline (Day 1), 40% (2/5) were PCR positive.
  - During subsequent timeframes, 27% (4/15) were positive (p=0,66).
- DHP System Present:
  - 5 baseline samples per unit were taken before DHP was installed
  - Additionally, 5 samples per unit were taken on days 7, 14, and 28 post-installation.
  - Pre-DHP installation, 70% (7/10) of samples were positive for *C. auris*.
  - Post-DHP installation, 16,7% (5/30), were positive for *C. auris* (p<0,05).
- There were no adverse impacts reported from patients, visitors, or personnel in association with operation of DHP systems.

	Results			Sample Totals	Fischer exact test: 0.6128 (not statistically significant); p=0.66 Percent Change Pre/Post: 13% reduction
	Negative	Positive			
<b>No DHP Present</b>					
Pre	3	2	5		
Post	11	4	15		
Grand Total	14	6	20		
<b>DHP Present</b>					
	Negative	Positive	Sample Totals	Fischer exact test: 0.0033 (statistically significant); p<0.05 Percent Change Pre/Post: 83.3% reduction	
Pre	3	7	10		
Post	25	5	30		
Grand Total	28	12	40		



## MATERIALS

- Sponge-Sticks with neutralizing buffer were used for sampling following the CDC protocol.
- PCR and reflex to culture if positive was conducted: 100 µL of the concentrated eluent is used to inoculate enrichment media that incorporates a high salt concentration and high incubation temperature to enrich *C. auris*. After incubation for 5 days, enriched cultures are plated onto CHROMagar *Candida* plates and incubated at 37° C. Plates were monitored for up to 2 days for growth of yeast with morphologies consistent with *C. auris*.
- Species ID: The identification of isolates suspected to be *C. auris* were determined by MALDI-TOF (MALDI Biotyper, Bruker Daltonics, Billerica, MA) using the Bruker and MicrobeNet (<https://microbenet.cdc.gov/>) databases; species-level identification is confident for scores ≥ 2,0.

## CONCLUSIONS

This study suggests that continuous DHP™ is effective in reducing surface *C. auris* contamination in a variety of patient and healthcare worker surfaces.

Further study is warranted to better characterize the potential for DHP to decrease risk of *C. auris* transmission in the health care setting.

## REFERENCES

- Information can be found at: <https://www.cdc.gov/fungal/candida-auris/index.html>
- Information can be found at: <https://www.cdc.gov/fungal/candida-auris/c-auris-drug-resistant.html>
- Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of *Candida auris* and Other *Candida* Species. *Infect Control Hosp Epidemiol.* 2017 Sep;38(9):1107-1109.
- Survival, Persistence, and Isolation of Emerging Multidrug-Resistant Pathogenic Yeast *Candida Auris* on a Plastic Health Care Surface. *Journal of Clinical Microbiology*; Vol 55, No. 10 <https://journals.asm.org/doi/10.1128/JCM.00921-17>
- Herman CK, Hess J, Cerra C. Dilute Hydrogen Peroxide Technology for Reduction of Microbial Colonization in the Hospital Setting. *Am J Infect Control* 2015; 43(6): S25-S26.
- Sanguinet J, Lee C. An effective and automated approach for reducing infection risk from contaminated privacy curtains. *Am J Infect Control.* 2021 Jun 11:S0196-6553(21)00402-8. doi: 10.1016/j.ajic.2021.06.004.
- Sanguinet J, Edmiston C. Evaluation of dry hydrogen peroxide in reducing microbial bioburden in a healthcare facility. *Am J Infect Control.* 2021 Aug;49(8):985-990. doi: 10.1016/j.ajic.2021.03.004.
- Ramirez M, Matheu L, Gomez M, Chang A, Ferrolino J, Mack R, et al. Effectiveness of dry hydrogen peroxide on reducing environmental microbial bioburden risk in a pediatric oncology intensive care unit. *Am J Infect Control.* 2021;49(5):608-613. doi:10.1016/j.ajic.2020.08.026
- Treatment with dry hydrogen peroxide accelerates the decay of severe acute syndrome coronavirus-2 on non-porous hard surfaces. *Am J Infect Control.* 2021 July 14

## ACKNOWLEDGEMENT

Nevada State Public Health Lab- PCR Testing